Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Trastuzumab Antibody Kit ELISA

Reactivité: Humain, Souris, Rat Colorimetric Bridging ELISA 31.25-125 ng/mL Plasma, Serum
N° du produit ABIN4886400
  • Antigène Tous les produits Trastuzumab Antibody
    Trastuzumab Antibody
    Reactivité
    Humain, Souris, Rat
    Méthode de détection
    Colorimetric
    Type de méthode
    Bridging ELISA
    Gamme de detection
    31.25-125 ng/mL
    Seuil minimal de détection
    31.25 ng/mL
    Application
    ELISA
    Fonction
    Quantification of antibodies to Trastuzumab
    Type d'échantillon
    Plasma, Serum
    Analytical Method
    Quantitative
    Specificité
    Anti-Trastuzumab antibodies
    Attributs du produit
    This immunogenicity assay employs the bridging ELISA technique.
    Ingrédients
    Coated microtiter plate, 96 wells
    QC samples - 4x50ul
    10X wash buffer - 25ml
    Assay buffer - 50ml
    1000X secondary antibody - 17ul
    1000X detection reagent - 17ul
    TMB - 12ml
    TMB stop solution - 12ml
    Plate sealers - 3
    Matériel non inclus
    Precision pipettes calibrated to deliver 5-1000μL
    Multi-channel pipette calibrated to deliver 50-200μL
    Plate shaker
    Disposable tips
    Vortex-Mixer
    Distilled or de-ionized water
    Microplate reader capable of reading 450nm with background subtrac
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Volume d'échantillon
    15 μL
    Durée du test
    3.5 h
    Plaque
    Pre-coated
    Protocole
    The Trastuzumab immunogenicity assay employs the bridging ELISA technique. A precoated 96 well capture antibody plate is provided. Quality control and test samples are pipetted into the appropriate wells. Anti-Trastuzumab present in biological matrices binds the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Trastuzumab present in test samples. Four levels of QC samples give a qualitative reference signal which can be used to determine the level (High, Medium, Low, Negative) of anti-Trastuzumab antibody in the unknown samples.
    Préparation des réactifs

    Prepare only the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 2 mL concentrate to 18 mL ultra-pure water). Mix well. 2. Secondary antibody (1X) Preparation: Dilute secondary antibody with assay buffer 1/1000 before use (for examples add 12 μL concentrate to 12 mL of assay buffer). Mix well. 3. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 12 μL concentrate to 12 mL of assay buffer). Mix well.

    Prélèvement de l'échantillon
    This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.
    Préparation de l'échantillon

    Dilute QC samples and test samples 1/10 with assay buffer (for example add 30μL of prepared calibrator or sample to 270μL of assay buffer). Mix well. Do not store diluted samples. If test samples are out of range, then they may be further diluted.

    Procédure de l'essai

    This immunogenicity assay employs the bridging ELISA technique. Capture antibody is precoated onto a 96 well microplate. Quality control and test samples are pipetted into the appropriate wells. AntiTrastuzumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Trastuzumab present in test samples. Three levels of QC samples give a qualitative reference signal which can be used to determine the level of anti-Trastuzumab antibody in the unknown samples. The color development is stopped and the intensity of the color is measured.

    Calcul des résultats
    1. Because anti-drug antibodies will vary in terms of affinity and concentration, this assay provides a qualitative readout. As such the user should use the comparable positive controls when comparing interassay results. The provided controls are tested for comparability between lots and can be traced. 2. The anti-drug antibody titers in the test samples will fall in the range of high, medium, low or negative. We recommend each lab develop their own statistical cutpoint using methodologies as described by G. Shankar, et al. (2008). (Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharmaceutical and Biomedical Analysis 48:1267-1281). 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with assay buffer and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.
    Précision du teste
    Intra-assay precision: < 10%
    Inter-assay precision: < 10%
    Restrictions
    For Research Use only
  • Agent conservateur
    Without preservative
    Précaution d'utilisation
    Read manual completely before beginning
    Stock
    -20 °C
    Stockage commentaire
    Store kit components at -20°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.
    Date de péremption
    12 months
  • Antigène Tous les produits Trastuzumab Antibody
    Trastuzumab Antibody
    Abstract
    Trastuzumab Antibody Produits
    Classe de substances
    Antibody
    Sujet
    Trastuzumab (Herceptin® ) is a humanized recombinant monoclonal antibody used for the treatment of primary breast cancers overexpressing human epidermal growth factor 2 (HER2). HER2 protein is overexpressed in 25-30 % of breast cancers.
    ID gène
    2064
Vous êtes ici:
Support technique